In addition, recent evidence has implicated IL-17 producing Vδ1 T cells in promoting tumor progression (30, 31), revealing the importance of characterizing IL-17 production and ensuring that γδ T-cell therapies do not promote tumor growth. This evidence concerns the gene IL17A and neoplasm.